Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

A compilation of meropenem tissue distribution data

M Hutchison1, K L Faulkner, P J Turner

  • 1Zeneca Pharmaceuticals, Mereside, Macclesfield, Cheshire, UK.

The Journal of Antimicrobial Chemotherapy
|July 1, 1995
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Emergency treatment of peri-operative anaphylaxis: Resuscitation Council UK algorithm for anaesthetists.

Anaesthesia·2024
Same author

CDC field triage criteria accurately predicts outcomes in high impact trauma.

Journal of injury & violence research·2022
Same author

Thematic Analysis of Parent-Child Conversations About COVID-19: "Playing It Safe".

Journal of child and family studies·2021
Same author

Pre-existing influenza-specific nasal IgA or nasal viral infection does not affect live attenuated influenza vaccine immunogenicity in children.

Clinical and experimental immunology·2020
Same author

Initial Challenges of Caregiving During COVID-19: Caregiver Burden, Mental Health, and the Parent-Child Relationship.

Child psychiatry and human development·2020
Same author

Comment on 'Four-year data from use of the nut and soya allergy testing protocol before treatment with isotretinoin and alitretinoin'.

Clinical and experimental dermatology·2020

Meropenem effectively penetrates body tissues and fluids, supporting its use for various infections. Recommended dosages ensure adequate therapeutic concentrations for common pathogens and meningitis.

Area of Science:

  • Pharmacology
  • Infectious Diseases
  • Clinical Pharmacy

Background:

  • Meropenem is a broad-spectrum carbapenem antibiotic.
  • Understanding meropenem's distribution in body fluids and tissues is crucial for optimizing treatment regimens.

Purpose of the Study:

  • To compile and analyze meropenem concentration data in body fluids and tissues.
  • To compare these concentrations with minimum inhibitory concentration (MIC) data of pathogens.
  • To evaluate the clinical efficacy of proposed meropenem dosing strategies.

Main Methods:

  • Compilation of meropenem concentration data from published studies and clinical trials.
  • Comparison of tissue and fluid concentrations with pathogen MIC values.
  • Analysis of pharmacokinetic data to support dosing recommendations.

Related Experiment Videos

Main Results:

  • Meropenem demonstrates widespread and rapid penetration into interstitial fluid across various tissues.
  • Proposed dosages (500 mg or 1 g thrice daily) provide adequate tissue concentrations for common pathogens.
  • Higher doses (40 mg/kg or 2 g thrice daily) are recommended for meningitis due to cerebrospinal fluid (CSF) penetration.

Conclusions:

  • Meropenem distributes rapidly into interstitial fluid, achieving clinically effective tissue concentrations.
  • The data support the therapeutic efficacy of meropenem as observed in clinical trials.
  • Dosing adjustments are supported for specific conditions like meningitis based on tissue penetration data.